HC Wainwright Reaffirms “Buy” Rating for Actinium Pharmaceuticals (NYSE:ATNM)

Actinium Pharmaceuticals (NYSE:ATNM)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $4.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 166.67% from the company’s current price.

A number of other analysts also recently weighed in on ATNM. Maxim Group dropped their target price on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. StockNews.com lowered shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Finally, B. Riley lowered shares of Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the company from $16.00 to $2.00 in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.40.

Actinium Pharmaceuticals Stock Down 9.1 %

NYSE ATNM opened at $1.50 on Friday. The company’s 50-day moving average price is $1.79. Actinium Pharmaceuticals has a twelve month low of $1.33 and a twelve month high of $10.24. The stock has a market capitalization of $46.79 million, a P/E ratio of -0.99 and a beta of 0.14.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Actinium Pharmaceuticals by 6.0% during the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock valued at $11,325,000 after acquiring an additional 82,113 shares during the last quarter. Virtu Financial LLC raised its position in Actinium Pharmaceuticals by 319.2% during the 1st quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock valued at $642,000 after purchasing an additional 62,459 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Actinium Pharmaceuticals by 28.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock worth $639,000 after buying an additional 19,035 shares during the period. Rhumbline Advisers grew its position in shares of Actinium Pharmaceuticals by 23.4% in the 2nd quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after buying an additional 7,525 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new position in shares of Actinium Pharmaceuticals during the second quarter valued at approximately $142,000. Hedge funds and other institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).